Portal de Periódicos da CAPES

Association Between Immune-Related Adverse Events During Anti–PD-1 Therapy and Tumor Mutational Burden

2019; American Medical Association; Volume: 5; Issue: 11 Linguagem: Inglês

10.1001/jamaoncol.2019.3221

2374-2445

David Bomze, Omar Hasan Ali, Andrew Bate, Lukas Flatz,

Colorectal Cancer Treatments and Studies

This database study compares surveillance data on immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors to determine whether irAEs experienced during anti–PD-1 therapy correlate with tumor mutational burden across 18 cancer types.